Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 10, 2020 00:50 ET | Source: Enochian Biosciences, Inc.

Enochian BioSciences to Present to Investors at 22nd Annual H.C. Wainwright Global Investment Conference

LOS ANGELES, Sept. 10, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today...
July 27, 2020 08:00 ET | Source: Enochian Biosciences, Inc.

Distinguished Scientific Leaders to Join Enochian BioSciences Hepatitis B Scientific Advisory Board

Drs. Carol Brosgart, Peter Revill and Fabien Zoulim will advise on development of a cure for Hepatitis B LOS ANGELES, July 27, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, a...
June 08, 2020 07:30 ET | Source: Enochian Biosciences, Inc.

Enochian BioSciences Announces Its Successful Completion of FDA INTERACT Meeting for a Potential Cure for HIV

Company encouraged by strong alignment with views of FDA’s CBER regarding ENOB-HV-01LOS ANGELES, June 08, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) - Enochian BioSciences, Inc., a company focused on...
May 13, 2020 08:00 ET | Source: Enochian Biosciences, Inc.

Enochian Biosciences Announces Three Scientific Presentations on Potential HIV and HBV Cures

• First presentation of a novel approach to potentially cure HIV - An in vivo study demonstrated a 164 percent increase in engraftment of genetically modified cells Poster Presentation -...
April 09, 2020 10:00 ET | Source: Enochian Biosciences, Inc.

Enochian Biosciences Announces Scientific Presentations at the American Society of Cell and Gene Therapy (ASCGT) Annual Meeting

Three of three abstracts were accepted for presentation at the Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT);The presentations advance the scientific foundation of Enochian’s...
February 24, 2020 07:30 ET | Source: Enochian Biosciences, Inc.

Enochian Biosciences Announces FDA INTERACT Meeting for a Potential Cure for HIV

FDA has granted Enochian an INTERACT meeting for its innovative approach to autologous stem cell transplantation as a potential cure for HIV. INTERACT is the first available FDA interaction and is a...
February 03, 2020 07:30 ET | Source: Enochian Biosciences, Inc.

Enochian Biosciences Acquires an Exclusive License for a Novel Hepatitis B Virus Potential Treatment or Cure

LOS ANGELES, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious diseases and cancer, announces that it has finalized the...
January 06, 2020 07:30 ET | Source: Enochian Biosciences, Inc.

Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious disease and cancer, announces the appointment of two board members:

- Gregg Alton, the former interim CEO of Gilead Sciences, a company he served in many key roles during his more than 20 year tenure, and; - Carol Brosgart, MD, Clinical Professor of Medicine at the...
December 10, 2019 07:00 ET | Source: Enochian Biosciences, Inc.

Enochian Biosciences Announces Scientific Presentation of a Novel Approach to Potentially Cure Hepatitis B Virus

A new gene therapy kills up to 98 percent of HBV infected cells but not uninfected cells. Results from a commonly used mouse model to study HBV confirmed the HBV-infected cell-specific killing effect...
November 25, 2019 07:00 ET | Source: Enochian Biosciences, Inc.

Enochian Biosciences Expands its Infectious Disease Pipeline by Entering into an Agreement in Principle to Acquire an Exclusive License for a Novel Hepatitis B Virus Treatment

Agreement provides Enochian with exclusive rights to develop and commercialize a HBV treatment with a novel mechanism of actionAbstract accepted highlighting the in vivo and in vitro data from...